Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Sirnaomics Strengthens its IP Position

Published: Friday, July 11, 2014
Last Updated: Friday, July 11, 2014
Bookmark and Share
Advancing the Company's novel siRNA therapeutics programs.

Sirnaomics, Inc. has announced that the company has received an Issue Notification from United States Patent and Trademark Office (USPTO) for a patent entitled "Multi-Targeted RNAi Therapeutics for Scarless Wound Healing of Skin" (US 8,735,567 B2, PCT/US2008/012498).

This USPTO issuance, combined with a similar success for a Chinese patent (ZL 200880124132.8) provides a solid foundation and protection for the company's leading siRNA therapeutic project under development both in the USA and in China.

Sirnaomics is a leading biopharmaceutical company active in discovery and development of siRNA therapeutics. The company's mission is to advance siRNA therapeutics by using its proprietary multi-targeted siRNA design and screening together with proprietary nanoparticle-mediated siRNA delivery vehicles. Through in-house efforts and collaborations, Sirnaomics has developed three generations of peptide nanoparticle-based siRNA delivery systems: self-assembled nanoparticles, ligand-directed nanoparticles, and infrared-activated nanoparticles.

Each formulation is adapted to different therapeutic applications. Based on its proprietary technologies, Sirnaomics has developed a rich pipeline of siRNA therapeutic candidates, including STP705 for prevention and treatment of skin hypertrophic scars, STP702 for prophylaxis and therapeutics against influenza infection, and STP523 for treatment of solid tumor.

The recent issued patent plus two additional issued patents, "Compositions for Treating Respiratory Viral Infections and Their Use" (US 8,691,781 B2, PCT/US2005/040048) and "Compositions and Methods Using siRNA Molecules for Treatment of Gliomas" (US 8,541,568 B2, PCT/US2009/003196), strengthen Sirnaomics' intellectual property portfolio covering the company's technology and siRNA therapeutics products.

"Intellectual property landscape for RNAi therapeutics has been emerging very differently today comparing 7-8 years ago. With three issued patents and a number of patent applications plus those licensed in IPs, Sirnaomics is well positioned for our siRNA therapeutic product development and technology advancement," said the Founder and President of the company, Dr. Patrick Y. Lu. "We will continue building our proprietary technology while pushing forward the leading siRNA therapeutic programs into clinics both in US and China." Dr. Lu further emphasized, "Sirnaomics' dual-targeted siRNA drug design and peptide nanoparticle delivery platform allow a great chance of success of our leading siRNA therapeutic candidates."

"Sirnaomics patent portfolio and product pipeline represent a clear leading position among privately held companies in the field," commented the recently appointed new CEO, Dr. Marc Lemaitre. "The ongoing efforts to start clinical studies with the leading siRNA therapeutic candidate STP705 both in the USA and in China are creating tremendous value for the company. We expect successful clinical studies for the leading compound and following candidates to further validate and reinforce the value of the company's intellectual property."

Dr. Lemaitre added, "More importantly, these therapeutic candidates are addressing unmet clinical needs with broad market potential."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sirnaomics Seals Partnership Deal for Development of RNAi Therapeutics in China
Sirnaomics, Inc. have announced that the company has cemented a partnership with a Chinese pharmaceutical company for development of its small interfering RNA (siRNA) therapeutic (STP705) for scarless wound healing.
Friday, December 03, 2010
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos